NASDAQ · GLYC
Healthcare · Biotechnology
$15.71
Down-$0.45 (-2.76%)
Updated Sep 14, 2026, 4:58 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
GLYC does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning GLYC.
GLYC research
Company profile and research snapshot.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 21, 2025 | Cantor Fitzgerald | Overweight | — |
| Jul 26, 2024 | TD Cowen | Hold | — |
| Jun 4, 2024 | HC Wainwright & Co. | Neutral | — |
| May 6, 2024 | HC Wainwright & Co. | Neutral | — |
| Mar 27, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jan 13, 2025
Avacta Therapeutics, a life sciences company, has appointed Brian Hahn as its new Chief Financial Officer. Hahn brings over 25 years of senior financial and operational experience in the biopharmaceutical industry, including leading the IPO and financial operations of GlycoMimetics.
GlobeNewswire Inc. · Nov 5, 2024
Monteverde & Associates PC, a class action law firm, is investigating the proposed merger between GlycoMimetics, Inc. and First Crescent Biopharma, Inc. Under the terms of the agreement, the pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company.
Benzinga · Oct 29, 2024
GlycoMimetics announced a merger with Crescent Biopharma and secured $200 million in funding to advance its oncology pipeline, causing its stock to surge on Tuesday.
GlobeNewswire Inc. · Aug 14, 2024
Apollomics reported progress in its vebreltinib program, including new data in non-CNS MET fusion tumors and NSCLC with MET amplification. The company also announced the closure of its uproleselan program due to negative Phase 3 results from its licensor, GlycoMimetics.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLYC.
No results
No recent SID articles mention GLYC.
